Meitheal Pharmaceuticals, Inc.

We are excited to announce the official launch of Methylene Blue Injection, USP, a trusted solution for the treatment of acquired methemoglobinemia in pediatric and adult patients. About Methylene Blue Injection, USP: Methylene Blue Injection, USP is an oxidation-reduction agent indicated for the treatment of acquired methemoglobinemia — a condition that can lead to reduced oxygen delivery in the body. This launch reinforces Meitheal’s commitment to providing reliable, high-quality medications for critical patient care. Learn more about Methylene Blue Injection, USP here: https://lnkd.in/gRmiBYDY Think sustainability, Think Meitheal.

With its breathtaking coastal beauty and historic charm, Amelia Island provides the perfect setting for this year’s Association for Accessible Medicines (AAM) Annual Meeting. As industry leaders come together to discuss the future of generics and biosimilars, Meitheal remains committed to ensuring a reliable supply of high-quality, essential medicines that enhance patient care and improve access across the United States. As we continue to expand our portfolio, including generics, biologics, and biosimilars, we look forward to engaging with our peers and shaping sustainable healthcare solutions for the future. Think sustainability, think Meitheal. #Generics #Biologics #Biosimilars

Today, we celebrate 8 incredible years since Meitheal's humble beginnings in 2017. Over this time, we have made remarkable strides in the generic pharmaceuticals space and started new ventures into brands and biologics while staying true to our mission of simplifying access to life-changing medicine for the common good. We are proud of all that we have accomplished and look forward to continuing to make a difference in the years to come.

We are thrilled to announce the official launch of Alprostadil Injection, USP (500 mcg/mL, Single-Dose Vial) — an essential medication designed to support critical care in neonates with congenital heart defects. Alprostadil Injection, USP is indicated as palliative therapy to temporarily maintain the patency of the ductus arteriosus in neonates with congenital heart defects until corrective or palliative surgery can be performed. Conditions include: Pulmonary atresia or stenosis, Tricuspid atresia, Tetralogy of Fallot, Interruption of the aortic arch, Coarctation of the aorta and Transposition of the great vessels. At Meitheal Pharmaceuticals, we remain dedicated to delivering high-quality, life-saving medications to support healthcare providers and enhance patient care. Learn more about Alprostadil Injection, USP here: https://lnkd.in/gQgqCWxj

At Meitheal, our mission is to advance patient care by ensuring a reliable supply of high-quality, essential medications. We are proud to participate in the annual J.P. Morgan Healthcare Conference in San Francisco this week to highlight how our growing portfolio, including brands and biologics, reflects our commitment to sustainable healthcare solutions across the United States. We look forward to connecting with industry leaders and sharing our vision for empowering healthcare providers and improving patient outcomes. Think sustainability, think Meitheal. #pharmaceuticals #sustainability